NCT01558947Unknown2 期
Peri-operative Chemotherapy With ECX (Epirubicin + Cisplatin + Capecitabine) or XP (Capecitabine + Cisplatin) in the Treatment of Advanced Gastric Cancer: a Randomized, Multicenter, Parallel Control
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- the relapse-free survival time/rate
研究概览
简要总结
The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer.
详细描述
To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine + cisplatin）in advanced gastric cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female aged 18 to 70 years old.
- •The preoperative evaluation: gastric cancer patients, ≥ T2 or N +; or staging II, IIIA, IIIB.
- •Karnofsky score ≥ 70, life expectancy > 6 months.
- •Endoscopic biopsy diagnosis of gastric cancer, excluding non-Hodgkin's lymphoma, leiomyosarcoma and other mesenchymal tumors.
- •the blood and biochemical indicators of the subjects must meet the following criteria: Hb ≥ 9 g / dl; WBC ≥ 4,000 / mm3, ≤ 12000 / mm3; PLT ≥ 100,000/mm3; GOT, GPT within twice the institutional limit,serum total bilirubin < 1.5 times the upper limit of normal, serum creatinine< 1.25 times the upper limit of normal and creatinine clearance rate ≥ 60ml/min, LVEF ≥ 60%.
- •have not received prior chemotherapy, radiotherapy and biological therapy.
- •signed informed consent.
- •must accept the standard D2 or D2 + radical gastrectomy.
- •with good compliance.
排除标准
- •pregnancy, breast-feeding women.
- •allergy with chemotherapy drugs or metabolic disorder.
- •the history of organ transplants (including bone marrow transplantation and autologous peripheral stem cell transplantation).
- •had long received systemic steroid treatment (Note: short-term users of withdrawal > 2 weeks can be selected.)
- •The existence of the peripheral nervous system disorders or significant neurological disorders and a history of central nervous system disorders.
- •patients with severe infection requires treatment.
- •patients associated with dysphagia, active peptic ulcer, incompleteness intestinal obstruction, active gastrointestinal bleeding, perforation.
- •severe liver disease (such as cirrhosis), kidney disease, respiratory disease or uncontrollable diabetes.
- •with other malignancies which were not cured.
- •EKG abnormalities or heart disease with apparent clinical symptoms, including congestive heart failure, coronary heart disease with symptoms, uncontrollable arrhythmia, hypertension, and heart attack within 12 months or III or IV grade myocardial infarction. Coronary heart disease with symptoms, uncontrollable arrhythmia, hypertension, and heart attack within 12 months or III or IV grade myocardial infarction.
研究组 & 干预措施
chemotherapy with ECX
Experimental
chemotherapy with ECX
干预措施: Peri-operative chemotherapy of ECX (Drug)
chemotherapy with XP
Experimental
chemotherapy with XP
干预措施: Peri-operative chemotherapy of XP (Drug)
结局指标
主要结局
the relapse-free survival time/rate
时间窗: 3 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study of Perioperative Chemotherapy in Gastric CancerGastric CancerNCT01633203Grupo Oncologico Cooperativo Chileno de Investigation61
撤回
3 期
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder CancerStage I Gallbladder Cancer AJCC v8Stage II Gallbladder Cancer AJCC v8Stage IIA Gallbladder Cancer AJCC v8Stage IIB Gallbladder Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage IIIA Gallbladder Cancer AJCC v8Stage IIIB Gallbladder Cancer AJCC v8NCT03579758Emory University
Unknown
3 期
Intra-operative Chemotherapy With 5-FU for Colorectal Cancer Patients Receiving Curative Resection: Efficacy and SafetyColorectal CancerNCT01465451Sun Yat-sen University695
招募中
2 期
Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction CancerGastric AdenocarcinomaEffects of ChemotherapyGastric CancerToxicity Due to ChemotherapyNCT04999332National Cheng-Kung University Hospital58
招募中
2 期
Phase II study of perioperative chemotherapy (preoperative XELOX+Bevacizumab/ postoperative XELOX) in patients with locally advanced rectal cancerRectal cancerJPRN-UMIN000013000Sano Hospital Masahito Kotaka, MD50